[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-function":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100638001",false,"NCT07625722","Thyroxine Supplementation in Small for Gestational Age (SGA) Infants With Birth Weight \u003C1500g and TSH 6-20 mIU\u002Fml","Growth and Neurodevelopmental Outcomes at Two Years of Age After Postnatal Thyroid Hormone Supplementation in SGA Infants With Birth Weight \u003C1500g and TSH 6-20 mIU\u002Fml","Inclusion Criteria:\n\n* Preterm infants born Small for Gestational Age (SGA) with a birth weight \\\u003C 1500g；\n* Admitted to a participating Neonatal Intensive Care Unit (NICU) within 7 days of birth；\n* Serum concentrations of TSH, FT4, and FT3 are measured weekly during the first and second weeks of life，any single TSH measurement during this period is between 6 and 20 mIU\u002FmL；\n* Written informed consent obtained from the parents.\n\nExclusion Criteria:\n\n* Diagnosis of Congenital Hypothyroidism (CH) with serum TSH \\> 20 mIU\u002FmL within the first 2 weeks of life and receiving L-T4 treatment;\n* Persistent serum TSH \\\u003C 6 mIU\u002FmL throughout the first 2 weeks;\n* Elevated thyroid hormone levels(T3, T4, FT3, or FT4) above the reference range within the first 2 weeks;\n* Diagnosis of Grade III or IV Intraventricular Hemorrhage (IVH) within the first 2 weeks of life;\n* Presence of major congenital malformations of vital organs or known chromosomal\u002Fgenetic disorders;\n* History of maternal thyroid disease or maternal use of thyroid-related medications.","ALL","2 Weeks",{"count":18,"type":19},106,"ESTIMATED","INTERVENTIONAL",[22],"NA","The primary objective of this clinical trail is to evaluate whether early supplementation of levothyroxine (L-T4) at a dosage of 8 ug\u002Fkg\u002Fd, initiated in the second week of life, improves physical growth and neurodevelopmental outcomes at 2 years of corrected age in Small for Gestational Age (SGA) infants with birth weights \\\u003C 1500g and TSH levels between 6 and 20 mIU\u002Fml. Preterm infants in the intervention group will receive 8 ug\u002Fkg\u002Fd of L-T4, while the control group will receive no supplementation. Physical growth will be assessed through height, weight, and head circumference, while neurodevelopmental status will be evaluated using the Bayley-IV scales and cranial MRI imaging findings.",[25,26,27,28],"Thyroid Function","Preterm","SGA and Growth","Neurodevelopment Outcome","NOT_YET_RECRUITING","2026-05-29",{"date":32,"type":33},"2026-06-04","ACTUAL",{"date":35,"type":19},"2026-06-20",{"date":37,"type":19},"2029-06-20",{"name":39,"class":40},"Shandong Provincial Hospital","OTHER_GOV",""]